T-ALL-CR患者CD34+细胞源DC生物学效应及扶正透毒祛毒复方干预研究

Minimal Residual Disease (MRD) is the main recurrent reason for Acute leukemias after a palliation. therefore ,many researchers focus on rebalancing the internal environment and restoring the normal immunity elimination to clear up residual leukemia cells.It was found that Leukemia patients in remission were usually immunocompromised ,their immune cells could not efficiently present leukemia or tumor antigen to T cells to clear up Leukemia cells.As the potent professional antigen present cell, dendritic cells(DC) can process and present antigen by antigenic determinant combined with MHC-I or MHC-II molecule to CD4+T cells or CD8+T cells,hence DC play an important role in the initiation for cell immunity. Obviously,improving the number and functions of DC is the key to eliminate leukemia cells efficiently. To explore the solution to MRD, our study is based on the pathogenesis theory of "deficiency in vital qi and pernicious influence stayed in Yin-phase " ,guided by the treatment philosophy of"strengthening vital qi,inducing out and dispelling evils" .Aiming new treatments and drug for MRD , establishing the principle and experiment foundations for all above,we research the biological effect of Fuzheng Toudu Qudu Decoction (FTQD) on CD34+DC from T-ALL-CR patients by DC culture combined with neuropharmacology method and flow cytometry.

微小残留病（MRD）是急性白血病缓解后复发的根本原因，使失去平衡的机体状态恢复正常，恢复机体对白血病细胞的免疫清除能力，彻底清除残留的微量白血病细胞是目前研究的热点、难点。研究发现缓解后白血病患者免疫功能低下，不能有效提呈白血病细胞肿瘤抗原，触发T细胞免疫监视而清除白血病细胞。其关键就在于肿瘤抗原的有效提呈。DC是最强有力的肿瘤抗原提呈细胞，将内噬抗原加工处理后以MHCⅡ类或MHCⅠ类分子方式提呈给CD4+T细胞或CD8+T细胞启动细胞免疫，提高患者DC的数量和改善DC的功能是机体能否有效清除白血病细胞的关键。本研究以微小残留白血病"正气虚弱、余毒留伏阴分"的病机理论及"扶正透毒祛毒"的治疗理论为指导，采用血清药理学、细胞培养、流式细胞技术等方法研究扶正透毒祛毒复方对T-ALL-CR患者CD34+细胞源DC生物效应的影响，为开拓微小残留白血病新的治疗方法及药物奠定理论和实验基础。